Page 336 - Personalised medicine of fluoropyrimidines using DPYD pharmacogenetics Carin Lunenburg

Chapter 13
48. Gamelin E, Delva R, Jacob J, et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(13):2099-2105.
49. Kaldate RR, Haregewoin A, Grier CE, Hamilton SA, McLeod HL. Modeling the 5-fluorouracil area under the curve versus dose relationship to develop a pharmacokinetic dosing algorithm for colorectal cancer patients receiving FOLFOX6. Oncologist. 2012;17(3):296-302.
50. Moloney M, Faulkner D, Link E, et al. Feasibility of 5-fluorouracil pharmacokinetic monitoring using the My-5FU PCM system in a quaternary oncology centre. Cancer Chemother Pharmacol. 2018;82(5):865-876.
51. Lee JJ, Beumer JH, Chu E. Therapeutic drug monitoring of 5-fluorouracil. Cancer Chemother Pharmacol. 2016;78(3):447-464.
52. Bocci G, Barbara C, Vannozzi F, et al. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. Clin Pharmacol Ther. 2006;80(4):384-395.
53. Di Desidero T, Barbara C, Orlandi P, et al. Prevention of Capecitabine Toxicity Using a 5-FU Test Dose. Clin Cancer Drugs. 2017;4(2):112-121.
54. vanStaverenMC,Theeuwes-OonkB,GuchelaarHJ,VanKuilenburgABP,MaringJG.Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency. Cancer Chemother Pharmacol. 2011;68(6):1611-1617.
55. MO. Dutch Association for Medical Oncology. “Result survey screening for DPD deficiency”. Dutch Medical Oncology Journal. 2016;19(6):12-15.
56. Lunenburg CATC, Guchelaar HJ, van Schaik RHN, Neumaier M, Swen JJ. Confirmation practice in pharmacogenetic testing; how good is good enough? Clin Chim Acta. 2018.
57. Lunenburg CATC, Henricks LM, van Kuilenburg ABP, et al. Diagnostic and Therapeutic Strategies for Fluoropyrimidine Treatment of Patients Carrying Multiple DPYD Variants. Genes. 2018;9(12).
58. Meulendijks D, Cats A, Beijnen JH, Schellens JH. Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity
- Ready for clinical practice? Cancer Treat Rev. 2016;50:23-34.
59. van Kuilenburg ABP, Meijer J, Maurer D, et al. Severe fluoropyrimidine toxicity due to novel and
rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and
mRNA splicing. Biochim Biophys Acta Mol Basis Dis. 2017;1863(3):721-730.
60. Ciccolini J, Gross E, Dahan L, Lacarelle B, Mercier C. Routine dihydropyrimidine dehydrogenase testing for anticipating 5-fluorouracil-related severe toxicities: hype or hope? Clin Colorectal
Cancer. 2010;9(4):224-228.
61. Mattison LK, Fourie J, Hirao Y, et al. The uracil breath test in the assessment of dihydropyrimidine
dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-
13C]dihydrouracil. Clin Cancer Res. 2006;12(2):549-555.
62. Mattison LK, Ezzeldin H, Carpenter M, Modak A, Johnson MR, Diasio RB. Rapid identification
of dihydropyrimidine dehydrogenase deficiency by using a novel 2-13C-uracil breath test. Clin
Cancer Res. 2004;10(8):2652-2658.
63. Cunha-Junior GF, De Marco L, Bastos-Rodrigues L, et al. 13C-uracil breath test to predict
5-fluorouracil toxicity in gastrointestinal cancer patients. Cancer Chemother Pharmacol. 2013;72(6):1273-1282.
334